Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of August 23, 2026, RARE trades at $25.98 with a market cap of $2.55B and a P/E ratio of -4.46. RARE moved +2.05% today. Year to date, RARE is +12.30%; over the trailing twelve months it is -12.50%. Its 52-week range spans $18.29 to $46.50. Analyst consensus is strong buy with an average price target of $54.06. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for RARE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $25.98 |
| Market Cap | $2.55B |
| P/E Ratio | -4.46 |
| EPS | $-5.82 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.50 |
| 52-Week Low | $18.29 |
| Volume | 2.04M |
| Avg Volume | 0 |
| Revenue (TTM) | $717.21M |
| Net Income | $-585.97M |
| Gross Margin | 0.00% |
18 analysts cover RARE: 0 strong buy, 16 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $54.06.